Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVEJ. Clin. Oncol 2020 Aug 21;[EPub Ahead of Print], SRD Johnston, R Hegg, SA Im, IH Park, O Burdaeva, G Kurteva, MF Press, S Tjulandin, H Iwata, SD Simon, S Kenny, S Sarp, MA Izquierdo, LS Williams, WJ Gradishar
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.